Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P057 - Pembrolizumab + (ID 16)
00:00 - 00:00 | Author(s): E. Regala
It remains uncertain if there is an improvement of efficacy with the addition of a third agent in platinum-doublet chemotherapy as first line treatment of PD-L1 positive advanced non-small cell lung cancer. Pembrolizumab, an anti-PD-1 monoclonal antibody, has been effective as monotherapy in patients with advanced NSCLC. But there is still limited evidence on its combination with chemotherapy as first line treatment in the metastatic setting. Hence, we performed a meta-analysis of randomized controlled trials that compared the efficacy and safety of combining pembrolizumab with chemotherapy versus chemotherapy alone as first line therapy for advanced non-small cell lung cancer.
Extensive search of PubMed, Medline and Cochrane was done for articles published after 2015. Studies were limited to RCTs comparing combined pembrolizumab and chemotherapy VS chemotherapy alone as first line treatment in advanced NSCLC. Outcomes measured included overall survival and progression-free survival in 5 yrs and 10 yrs. Statistical analysis was done using Review manager V5.3.
For pembrolizumab plus chemotherapy VS chemotherapy alone, pooled odds ratio of overall survival in 5 yrs and 10 yrs were 0.62 (95% CI: 0.21-1.85) and 0.67 (95% CI 0.50-0.91) respectively. Pooled odds ratio of progression-free survival in 5 yrs and 10 yrs were 0.39 (95% CI 0.29-0.54) and 0.51 (95% CI 0.34-0.76) respectively. Results demonstrate a significant survival benefit in giving pembrolizumab with chemo
Pembrolizumab plus chemotherapy improved overall survival and progression-free survival in patients with PD-L1 positive advanced NSCLC. We encourage using this regimen as first line treatment.